Risk assessment of bovine spongiform encephalopathy transmission through bone graft material derived from bovine bone used for dental applications

Journal of Periodontology

Volumn 70, Issue 9, 1999, Pages 1053-1063

  Sogal, A ^a   Tofe, A J ^b  

^a CeraMed Corporation   (United States)

^b NONE

Author keywords

Bone substitutes; Encephalopathy, bovine spongiform; Models, biological; Risk factors

Indexed keywords

ALPHA TRICALCIUM PHOSPHATE; ALPHA-TRICALCIUM PHOSPHATE; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE MONOBASIC; DICALCIUM PHOSPHATE ANHYDROUS; HYDROXYAPATITE; TETRACALCIUM PHOSPHATE;

ALGORITHM; ANIMAL; ARTICLE; BIOLOGICAL MODEL; BONE PROSTHESIS; BONE TRANSPLANTATION; BOVINE SPONGIFORM ENCEPHALOPATHY; CATTLE; CHEMISTRY; CRYSTALLOGRAPHY; DISEASE TRANSMISSION; HUMAN; INFRARED SPECTROSCOPY; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; TRANSPLANTATION; X RAY DIFFRACTION; XENOGRAFT;

ALGORITHMS; ANIMALS; BONE SUBSTITUTES; BONE TRANSPLANTATION; CALCIUM PHOSPHATES; CATTLE; CRYSTALLOGRAPHY; DURAPATITE; ENCEPHALOPATHY, BOVINE SPONGIFORM; HUMANS; MODELS, BIOLOGICAL; RISK ASSESSMENT; RISK FACTORS; RISK MANAGEMENT; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION, HETEROLOGOUS; X-RAY DIFFRACTION;

EID: 0033191071     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.1999.70.9.1053     Document Type: Article

References (32)

1. Brown P, Liberski PP, Wolff A, et al. Resistance of scrapie infectivity to steam autoclaving after formaldehyde fixation and limited survival after ashing at 360°C: Practical and theoritical Implications. J Infect Dis 1990;161:467-472.
2. Taylor DM, McConnell I, Fernie K. The effect of dry heat on the ME7 strain of mouse-passaged scrapie agent. J Gen Virol 1996;77:3161-3164.
3. Bolton DC, McKinley MP, Prusiner SB. Identification of a protein that purifies with the scrapie prion. Science 1982;218:1309-1311.
4. Bolton DC, McKinley MP, Prusiner SB. Molecular characteristics of the major scrapie prion protein. Biochemistry 1984;23:5898-5906.
5. Moore RC, Melton DW. Transgenic analysis of prion diseases. Mol Hum Reprod 1997;3:529-544.
6. United States Pharmacopiea. Nitrogen Determination. Rockville, MD: United States Pharmacopeial Convention, Inc.; 1998:461.
7. American Society for Testing and Materials. Standard Test Method for Total and Organic Carbon in Water by High Temperature Oxidation and by Coulometric Detection. 1988:ASTM D4129-88.
8. Guidelines on safety measures in connection with medicinal products containing body materials obtained from cattle, sheep, or goats for minimizing the risk of transmission of BSE and scrapie. 2-16-1994; Federal Ministry of Health (Germany). Federal Bulletin No. 40.
9. Public health issues related to animal and human spongiform encephalopathies: Memorandum from a WHO meeting. 1992; Bulletin of the World Health Organization. No. 70(2)183-90.
10. Bader F, Davis G, Dinowitz M, et al. Assessment of risk of bovine spongiform encephalopathy in pharmaceutical products, Part 1. BioPharm 1998;11(1):20-30.
11. Bader F, Davis G, Dinowitz M, et al. Assessment of risk of bovine spongiform encephalopathy in pharmaceutical products, Part 2: Example risk assessment for a hypothetical product. BioPharm 1998;11(3):18-30.
12. Public notice regarding approval and registration of medicinal products. Protection against medicinal risks, Grade II. 9-25-95; German Federal Institute for Medical Supplies and Medicinal Products. Federal Publicity No. 210-09.11.1995, S.11604.
13. Fowler BO. Infra-red spectra of hydroxyapatite, octa-calcium phosphate and pyrolysed octa-calcium phosphate. Arch Oral Biol 1966;11:477-492.
14. LeGeros, Raquel Z. Calcium phosphates in oral biology and medicine. In: Myers HM, ed. Monographs in Oral Science. New York: Karger; 1991.
15. American Society for Testing and Materials. Standard Specification for Composition of Anorganic Bone for Surgical Implants. 1995:ASTM F1581-95.
16. Kimberlin RH. An overview of bovine spongiform encephalopathy. Dev Biol Stand 1991;75:75-82.
17. Adams DH, Field EJ, Joyce G. Periodatean: Inhibitor of the scrapie agent? Res Vet Sci 1972;13:195-198.
18. Brown P, Rohwer RG, Green EM, et al. Effect of chemicals, heat and histopathological processing on high infectivity hamster-adaptable scrapie virus. J Infect Dis 1982;145:683-687.
19. Brown P, Gibbs CJ. Jr, Amiyx HL, et al. Chemical disinfection of Creutzfeldt Jakob disease virus. N Engl J Med 1982;306:1279-1282.
20. Brown P, Gibbs CJ. Jr, Gajdusek CD, et al. Transmission of Creutzfeldt Jakob disease from formalin-fixed, parafin-embedded human brain tissue. N Engl J Med 1986;315: 1614-1615.
21. Burger D, Gorham JR. Observation on the remarkable stability of transmissible mink encephalopathy virus. Res Vet Sci 1977;22:131-132.
22. Gajdusek CD, Gibbs CJ. Jr, Asher DM, et al. Precautions in medical care of, and in handling materials from patients with transmissible virus dementia (Creutzfeldt Jakob disease). N Engl J Med 1977;297:125-258.
23. Gajdusek CD, Gibbs CJ. Jr, Collins G, et al. Survival of Creutzfeldt Jacob disease virus in formolfixed brain tissue. N Engl J Med 1976;294:553.
24. Pattison IH. Resistance of the scrapie agent to formalin. J Comp Pathol 1965;75:159-164.
25. Rohwer RG. Scrapie infectious agent is virus-like in size and susceptibility to inactivation. Nature 1984;308: 658-562.
26. Tateishi J, Coga M, Sato Y, et al. Properties of the transmissible agent derived from chronic spongiform encephlopahty. Ann Neurol 1980;7:390-391.
27. Zlotnik I, Stamp JT. Scrapie in a Dorset Down ram. A confirmation of the histological diagnosis by means of intrecereberal inoculation of mice with formol fixed brain tissue. Vet Rec 1965;77:1178-1179.
28. Tateishi J, Tashima, T, Kitamoto T. Practical methods for chemical inactivation of Creutzfeldt-Jakob disease pathogen. Microbiol Immunol 1991;35:163-166.
29. Taylor DM, Woodgate SL, Atkinson MJ. Inactivation of the bovine spongiform encephalopathy agent by rendering procedures. Vet Rec 1995;137:605-610.
30. Ernst DR, Race RE. Comparative analysis of scrapie agent inactivation methods. J Virol Methods 1993;41: 193-202.
31. Greenlee JE. Containment precautions in hospitals for cases of Creutzfeldt Jacob disease. Infect Control 1982; 3:222-2223.
32. Comer P, Spouge J. Risks from Burning Rendered Products from the Over Thirty Month Scheme in Power Stations. A assessment report (No. C7243) prepared for the Environment Agency, England & Wales. London: DNV Technica; 1997.